These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6525604)

  • 41. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).
    Forastiere AA; Shank D; Neuberg D; Taylor SG; DeConti RC; Adams G
    Cancer; 1998 Jun; 82(11):2270-4. PubMed ID: 9610709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II ftorafur therapy in previously treated squamous cell cancers of the head and neck.
    Campbell M; Al-Sarraf M
    Cancer Treat Rep; 1980; 64(4-5):713-5. PubMed ID: 6775805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
    Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
    Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma.
    Steinberg L; Hassan M; Olmsted L; Sharan V; Stepnick D; Hoppel C; Mugharbil A; Subramanyan S; McGloin B; Mackay W; Strauss M
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-51-S19-56. PubMed ID: 9427267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Etoposide, pirarubicin and cisplatin(ETP) combined therapy of inoperable head and neck cancer].
    Kawakami T; Watanabe S; Ogawara T; Akagi S; Tamura S; Koide I; Ogawa A; Takiguchi S; Masuda Y
    Gan To Kagaku Ryoho; 1993 Apr; 20(5):669-72. PubMed ID: 8470928
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer.
    Creaven P; Raghavan D; Pendyala L; Perez R; Loewen G; Meropol N; Levine E; Hicks W
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):13-6. PubMed ID: 7481855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.
    Flood W; Lee DJ; Trotti A; Spencer S; Murphy B; Khuri F; DeConti R; Wheeler R; Forastiere AA
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):64-9. PubMed ID: 10210542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate.
    Scher HI; Yagoda A; Ahmed T; Watson RC
    J Clin Oncol; 1985 Feb; 3(2):224-8. PubMed ID: 3968552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies.
    Smith RE; Thornton DE; Allen J
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):41-6. PubMed ID: 7597432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I-II trial of methyl-GAG: a Southwest Oncology Group Pilot Study.
    Knight WA; Livingston RB; Fabian C; Costanzi J
    Cancer Treat Rep; 1979; 63(11-12):1933-7. PubMed ID: 526927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of aclacinomycin-A in head and neck cancer].
    Tsukuda M
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2335-41. PubMed ID: 6594077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
    Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of vindesine in advanced head and neck cancer.
    Cheng E; Young CW; Wittes RE
    Cancer Treat Rep; 1980; 64(10-11):1141-2. PubMed ID: 7459901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
    Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in advanced breast cancer. A Phase II trial of the Southwest Oncology Group.
    Knight WA; O'Bryan RM; Samal B; Costanzi JJ
    Invest New Drugs; 1984; 2(1):71-3. PubMed ID: 6469501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of methyl-glyoxal bis-guanylhydrazone (NSC 3296) in advanced ovarian cancer.
    Vogl SE; Pagano M; Horton J
    Am J Clin Oncol; 1984 Dec; 7(6):733-6. PubMed ID: 6528867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.